Ketamine Troches for OCD: Emerging Research

Ketamine Troches for OCD: What the Research Shows

Ketamine troches for OCD are an emerging, off-label option for people with obsessive-compulsive disorder who have not responded adequately to first-line therapy. Obsessive-compulsive disorder (OCD) is a mental health condition marked by intrusive, unwanted thoughts, known as obsessions, and repetitive behaviors or mental rituals, known as compulsions, performed to reduce the anxiety those thoughts create. According to the National Institute of Mental Health, OCD affects an estimated 2-3 percent of adults. First-line treatment combines high-dose selective serotonin reuptake inhibitors (SSRIs) with exposure and response prevention (ERP) therapy, a structured form of cognitive behavioral therapy that helps patients tolerate triggers without performing compulsions.

Despite these established options, 40-60 percent of OCD patients do not reach adequate remission on first-line treatment alone, and many remain significantly impaired after multiple treatment trials. For this treatment-resistant group, ketamine's effect on the brain's glutamate system has drawn growing research interest. The evidence is real but early, smaller in scope and less mature than the research base supporting ketamine for depression or PTSD, and no published trial has tested sublingual ketamine troches specifically for OCD. Our overview of the sublingual ketamine research covers how the evidence base differs across delivery methods and conditions.

The Glutamate Hypothesis of OCD

The historical explanation for OCD centered on serotonin dysregulation, an idea supported by the effectiveness of SSRIs. A growing body of neuroimaging and pharmacological research now points to the glutamate system as centrally involved in OCD as well. Glutamate is the brain's primary excitatory neurotransmitter, and NMDA receptors, the same receptors ketamine blocks, are critical modulators of the circuits implicated in OCD.

Cortico-Striato-Thalamo-Cortical (CSTC) Circuits

OCD is understood as a disorder of the cortico-striato-thalamo-cortical (CSTC) loop, a brain circuit that normally filters and gates repetitive thoughts and behaviors. In OCD, this circuit becomes hyperactive. The orbitofrontal cortex and caudate nucleus drive excessive loops of thought that manifest as obsessions, along with the compulsive behaviors people perform to neutralize them. Glutamate dysregulation in this circuit, specifically excess glutamate at corticostriatal synapses, contributes to that hyperactivation.

Evidence for Glutamate Involvement

Several lines of evidence support the glutamate hypothesis. Neuroimaging studies have found elevated glutamate in the caudate nucleus and anterior cingulate cortex of OCD patients. Riluzole, a glutamate modulator, has shown modest benefit in small OCD trials. Memantine, a low-affinity NMDA antagonist, has shown some benefit as an augmentation strategy. N-acetylcysteine, which modulates glutamate release, has also shown promise in OCD studies. None of these agents is as pharmacologically powerful as ketamine at the NMDA receptor, but together they support glutamate as a clinically relevant target in OCD.

How Ketamine Might Help OCD

Given the glutamate hypothesis, ketamine's NMDA receptor blockade provides a plausible mechanism for OCD treatment. By blocking NMDA receptors in hyperactivated CSTC circuits, ketamine may interrupt the pathological glutamate loops that maintain OCD symptoms, allow neuroplastic remodeling of compulsive circuits during the window after a session, reduce compulsive urges enough that ERP therapy can be practiced more effectively, and modulate the anxiety that drives compulsion performance. Timing ERP practice to occur during that post-session neuroplasticity window, rather than treating ketamine and ERP as separate interventions, may produce better outcomes than either approach used alone.

Clinical Evidence: What We Know

Rodriguez et al. (2013): The First Controlled Trial

The landmark study of ketamine for OCD is Rodriguez et al. (2013), published in Neuropsychopharmacology. It was a randomized, double-blind, placebo-controlled crossover trial using IV ketamine (0.5 mg/kg over 40 minutes) in 15 patients with treatment-resistant OCD. Half of the ketamine-treated patients met response criteria, defined as a 35 percent or greater reduction on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), compared to a much lower response rate in the placebo condition. Effects appeared within hours of infusion and, in some patients, persisted for several days to over a week. Fifteen patients is too small a sample for definitive conclusions, but the trial provided proof-of-concept evidence that ketamine can produce rapid OCD symptom reduction.

Subsequent Case Reports and Case Series

Case reports published since 2013 have documented meaningful OCD symptom reduction following ketamine in patients who had failed multiple prior treatments. A pattern emerges across these accounts: some patients respond dramatically, with more than 50 percent Y-BOCS reduction; some respond partially; and some do not respond, or experience temporary worsening. The proportion of robust responders appears lower than what is reported in depression trials, but the subset who does respond may have few other options left.

Sublingual and Troche Data

No published controlled trials have specifically examined sublingual ketamine for OCD. Clinical experience among practitioners who use troches for OCD exists but is largely unpublished. Extrapolating from IV data, sublingual administration at appropriately calibrated doses may produce similar effects, though ketamine's lower and more variable bioavailability by this route makes dose finding more difficult. Our sublingual ketamine therapy guide covers how absorption and dosing differ from IV or intranasal delivery.

Concurrent ERP Therapy Is Strongly Recommended

OCD treatment is incomplete without exposure and response prevention therapy, regardless of what medication is used alongside it. For patients using ketamine, the window of reduced compulsive urge and increased cognitive flexibility after a session is an opportunity to practice ERP exposures with more tolerance than usual. Working with a therapist who can guide ERP practice between sessions is strongly recommended, not optional.

The Anxiety Caveat

OCD patients typically carry significant baseline anxiety, and ketamine can temporarily amplify anxiety during the onset of its effects before the anti-anxiety and dissociative effects take hold. Conservative starting doses and thorough preparation before the first session matter more for this population than for patients without significant anxiety. Our troche safety guide covers how to prepare for a session and what to expect, and our onset and duration timeline explains how quickly effects build after dosing.

What OCD Patients Report

Among the small but growing group of patients who have tried ketamine for OCD, a consistent pattern shows up in clinical accounts. Many describe a temporary quieting of the obsessive mental loop during and immediately after sessions. Some experience this as profoundly relieving, a glimpse of what life without constant OCD feels like. How long that relief lasts varies widely, from hours to days to weeks. Repeat sessions appear necessary to maintain any benefit; a single session rarely produces lasting change.

Access and Cost Considerations

Ketamine troches for OCD are typically self-pay, since this use is off-label and not covered by insurance the way an FDA-approved medication would be. That is a meaningful difference from esketamine nasal spray, which is FDA-approved for treatment-resistant depression and can carry partial insurance coverage for that specific indication, but not for OCD. Our guide to the insurance coverage gap explains what is typically reimbursed and what is not, and our cost breakdown covers what factors into troche pricing.

Future Directions

Several research programs are examining ketamine for OCD, including studies combining ketamine with ERP to test whether the two work better together than either alone, efforts to identify biomarkers that predict which OCD patients are most likely to respond, and comparisons of different ketamine delivery routes. This is a rapidly developing area. Patients interested in enrolling in a trial can search current listings at ClinicalTrials.gov. For a related condition where the ketamine evidence base is more developed, see our overview of ketamine troches for PTSD.